Combo Craze: For PD-1s, Research Alliances Are The Order Of The Day
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Merck are the latest to study a new combination in the field of immuno-oncology, but PD-1 frontrunners including Merck, Bristol-Myers Squibb and Roche are already making headway testing multiple drug combinations in pursuit of the most effective and safest way to treat cancer.